

CITATION REPORT

List of articles citing

A randomized phase I pharmacokinetic trial comparing the potential biosimilar adalimumab (CinnoRA) with the reference product (Humira) in healthy volunteers

DOI: 10.1080/13543784.2020.1723000

Expert Opinion on Investigational Drugs, 2020, 29, 327-331.

Source: <https://exaly.com/paper-pdf/77416331/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2	A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta [®] in healthy Chinese male subjects. <i>Expert Opinion on Biological Therapy</i> , 2021 , 1-9	5.4	0
1	Critical Appraisal and Future Outlook on Anti-Inflammatory Biosimilar Use in Chronic Immune-Mediated Inflammatory Diseases. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 152023	5.3	